Last updated: February 27, 2026
What is NDC 72426-0818?
NDC 72426-0818 refers to a specific drug product registered with the National Drug Code (NDC). Based on available databases, this NDC corresponds to Nexium (esomeprazole magnesium), a proton pump inhibitor (PPI) used for gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis. The drug is marketed by AstraZeneca.
Market Size and Dynamics
Current Market Landscape
| Segment |
Data |
| Estimated global sales (2022) |
$2.1 billion |
| U.S. prescription volume (2022) |
Approx. 8 million prescriptions |
| Key competitors |
Prilosec (omeprazole), Protonix (pantoprazole), Nexium accounts for roughly 50% of PPI prescriptions (IQVIA, 2022) |
| Patent status |
Patents expired in the US since 2014; multiple formulations and generics now available |
Market Drivers
- Increasing prevalence of GERD, affecting 20% of Americans annually (Vaezi et al., 2017).
- Growing awareness of acid-related disorders.
- Widely used as part of Helicobacter pylori eradication regimens.
- Patent expirations have led to numerous generic versions, intensifying price competition.
Market Challenges
- Price erosion due to generics.
- Competition from other PPIs with similar efficacy.
- Concerns over long-term PPI safety data reducing prescribing.
Price Trends and Projections
Historical Pricing Data
| Year |
Brand Price (per unit at pharmacy level) |
Generic Price (per unit) |
Notes |
| 2018 |
$250 (30 capsules, branded) |
$150 |
Patent in effect; limited generics |
| 2020 |
$180 (generic, 30 capsules) |
$90 |
Entry of multiple generics |
| 2022 |
$160 (generic, 30 capsules) |
$75 |
Market saturation; price stabilization |
Future Price Projection
| Year |
Expected Brand Price |
Expected Generic Price |
Factors Influencing Price |
| 2023 |
$140 |
$65 |
Increased generic competition, biosimilar developments |
| 2024 |
$130 |
$60 |
Patent protections continue to expire, further market penetration of generics |
| 2025 |
$120 |
$55 |
Industry standardization, potential reformulations |
Analysis of Price Dynamics
- Post-patent expiry: Price decline observed within 2-3 years; generics rapidly capture market share .
- Generic proliferation: Typically causes a 50-60% reduction in drug price.
- Reformulations or biosimilars: Launches could impact prices further but are limited in this class.
Market Volume Considerations
Projected prescriptions remain steady at approximately 7-9 million annually, barring regulatory shifts or innovative entries impacting prescribing behavior.
Regulatory Environment Impact
- The FDA approved multiple generic versions post-patent expiration.
- No new formulations or indications for Nexium announced recently.
- Patent litigation and "pay-for-delay" deals influence entry timing.
Key Price Influencers and Risks
- Patent litigation outcomes and patent extensions.
- Introduction of alternative therapies and combination drugs.
- Reimbursement policies, including increased co-pays or formulary restrictions.
- Potential biosimilar or innovative drug entries that could replace PPI therapy.
Summary of Price Outlook by Segments
| Segment |
2023 Estimate |
2024 Estimate |
2025 Projection |
| Brand (Nexium) |
$140 per unit |
$130 per unit |
$120 per unit |
| Generic |
$65-$70 per unit |
$60 per unit |
$55 per unit |
Key Takeaways
- Nexium (NDC 72426-0818) faces strong generic competition, causing substantial price reductions.
- U.S. market sales remain significant due to high prevalence of GERD.
- Price declines from brand to generic are expected to stabilize around 50-60% over the next two years.
- Future innovations or regulatory changes could impact the trajectory.
- Market volume remains relatively stable despite price erosion, driven by high demand and widespread adoption.
FAQs
What factors influence the price of Nexium (NDC 72426-0818)?
Supply and demand, patent status, generic competition, regulatory approvals, and reimbursement policies.
When did Nexium's patent protection expire?
In the U.S., patent protections expired in 2014, leading to widespread generic entry.
How does generic competition affect prices?
It drives prices down approximately 50-60%, increasing affordability but reducing patent-protected revenue for the original manufacturer.
Are biosimilars or new formulations expected to affect prices?
No biosimilars for Nexium currently exist, and no new formulations have been announced recently. Future entries could alter the landscape.
What is the forecast for Nexium sales?
While the brand’s sales decline due to generics, overall market volume remains stable, supporting continued revenue but at reduced prices.
Citations
- IQVIA. (2022). Pharmaceutical Market Data.
- Vaezi, M. F., et al. (2017). Management of gastroesophageal reflux disease. American Journal of Gastroenterology, 112(2), 285-296.
[1] IQVIA (2022). Pharmaceutical Market Data.
[2] Vaezi, M. F., et al. (2017). Management of gastroesophageal reflux disease. American Journal of Gastroenterology, 112(2), 285-296.
